Omilia raised a $67 million Series B led by Expedition Growth Capital on August 6, 2026. The Athens/New York voice-first agentic CX company says live ARR topped $60M — >10× since Series A — with capital efficiency rare in the GenAI CX arms race.

Key facts

Who uses the product — and for what job

Users: contact-center and CX leaders at banks, insurers, utilities, government, and QSR.

Job: contain and resolve high-volume voice (and omnichannel) interactions with sub-second latency, auditability, and predictable cost — not a pilot chatbot that explodes the LLM bill.

Named logos include Capital One, Discover, RBC, DWP, PSEG, and Taco Bell (1,000+ drive-thrus / 38 states per company).

Omilia’s wedge vs “LLM for every utterance”: use the right tool for the job — deterministic flows for balance checks, generative agents where judgment is needed — on owned models so token pass-through does not own the P&L.

Why now

• Enterprises graduated from GenAI demos to production call volume.
• Token-priced CX stacks create CFO pushback at million-call scale.
• Regulated buyers want FedRAMP / PCI / HIPAA / GDPR paths, not lab sandboxes.
• QSR voice ordering and bank containment are measurable ROI stories, not vanity NPS.

Why Expedition — portfolio fit (growth equity lens)

Expedition markets itself as a transatlantic software & AI growth specialist ($1B+ AUM) that partners with founder-owned, capital-efficient leaders. Omilia’s six-year gap from Series A to a $67M B with $60M+ ARR is the textbook “use capital to accelerate, not survive” profile.

Likely founder rationale: pick growth equity that understands enterprise GTM and founder control, not a mega-fund that would force a burn race against Sierra/Decagon branding.

Competitive map

CEO Dimitris Vassos’s framing (via TechCrunch): you may have a bazooka, but contact centers still need a knife.

Market signal

~$60M ARR → $67M raise implies growth equity pricing discipline, not 2021 AI multiple theater. The category winners may be the vendors that own unit economics at 1M+ calls/day.

When not to treat Omilia as the only template

• Wrong for greenfield consumer chatbots with no concurrency or compliance burden.
• Wrong if your only proof is a LinkedIn demo — Omilia’s buyers care about FedRAMP and call containment.
• Wrong to ignore QSR edge cases; voice ordering still needs human escalation design.

Practical takeaway

• Founders (CX AI): Sell predictable cost + audit trails; owned models can be a CFO feature.
• Investors: Prefer capital-efficient voice platforms with named regulated logos over narrative-only agent demos.
• Operators: Benchmark containment and cost-per-resolved-contact at your peak concurrency, not vendor showcase traffic.

Sources

1. Omilia PR (Aug 6, 2026): https://omilia.com/resources/news/omilia-secures-67-million-in-series-b-funding-to-accelerate-global-expansion-of-its-agentic-cx-platform-for-large-enterprises/
2. TechCrunch: https://techcrunch.com/2026/08/06/omilia-raises-67m-to-scale-its-customer-support-platform/
3. Related: /2026-smallest-ai-13m-series-a-voice-infra · /2026-august-9-investment-news-roundup-agents-voice-health